Evidence map›Paper›PMID 24693270›Full record

ArticleGastroenterology & hepatology2012

Tumor factors associated with clinical outcomes in patients with hepatitis B virus infection and hepatocellular carcinoma.

Myron John Tong, Surachate Siripongsakun, Gaelen Stanford-Moore, Leeyen Hsu, Patrick Weijen Chang, Lawrence Mitchell Blatt

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Gastroenterology & hepatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2019
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Myron John TongDr. Tong is affiliated with the Liver Center of Huntington Medical Research Institutes in Pasadena, California and with the Pfleger Liver Institute and the Division of Digestive Diseases at the David Geffen School of Medicine of the University of California in Los Angeles, California. Dr. Siripongsakun is affiliated with the Pfleger Liver Institute and the Division of Digestive Diseases at the David Geffen School of Medicine of the University of California in Los Angeles, California and with Chalubhorn Hospital in Bangkok, Thailand. Ms. Stanford-Moore, Mr. Hsu, and Mr. Chang are affiliated with the Liver Center of Huntington Medical Research Institutes in Pasadena, California. Dr. Blatt is affiliated with Alios Biopharma in South San Francisco, California.
Surachate SiripongsakunDr. Tong is affiliated with the Liver Center of Huntington Medical Research Institutes in Pasadena, California and with the Pfleger Liver Institute and the Division of Digestive Diseases at the David Geffen School of Medicine of the University of California in Los Angeles, California. Dr. Siripongsakun is affiliated with the Pfleger Liver Institute and the Division of Digestive Diseases at the David Geffen School of Medicine of the University of California in Los Angeles, California and with Chalubhorn Hospital in Bangkok, Thailand. Ms. Stanford-Moore, Mr. Hsu, and Mr. Chang are affiliated with the Liver Center of Huntington Medical Research Institutes in Pasadena, California. Dr. Blatt is affiliated with Alios Biopharma in South San Francisco, California.
Gaelen Stanford-MooreDr. Tong is affiliated with the Liver Center of Huntington Medical Research Institutes in Pasadena, California and with the Pfleger Liver Institute and the Division of Digestive Diseases at the David Geffen School of Medicine of the University of California in Los Angeles, California. Dr. Siripongsakun is affiliated with the Pfleger Liver Institute and the Division of Digestive Diseases at the David Geffen School of Medicine of the University of California in Los Angeles, California and with Chalubhorn Hospital in Bangkok, Thailand. Ms. Stanford-Moore, Mr. Hsu, and Mr. Chang are affiliated with the Liver Center of Huntington Medical Research Institutes in Pasadena, California. Dr. Blatt is affiliated with Alios Biopharma in South San Francisco, California.
Leeyen HsuDr. Tong is affiliated with the Liver Center of Huntington Medical Research Institutes in Pasadena, California and with the Pfleger Liver Institute and the Division of Digestive Diseases at the David Geffen School of Medicine of the University of California in Los Angeles, California. Dr. Siripongsakun is affiliated with the Pfleger Liver Institute and the Division of Digestive Diseases at the David Geffen School of Medicine of the University of California in Los Angeles, California and with Chalubhorn Hospital in Bangkok, Thailand. Ms. Stanford-Moore, Mr. Hsu, and Mr. Chang are affiliated with the Liver Center of Huntington Medical Research Institutes in Pasadena, California. Dr. Blatt is affiliated with Alios Biopharma in South San Francisco, California.
Patrick Weijen ChangDr. Tong is affiliated with the Liver Center of Huntington Medical Research Institutes in Pasadena, California and with the Pfleger Liver Institute and the Division of Digestive Diseases at the David Geffen School of Medicine of the University of California in Los Angeles, California. Dr. Siripongsakun is affiliated with the Pfleger Liver Institute and the Division of Digestive Diseases at the David Geffen School of Medicine of the University of California in Los Angeles, California and with Chalubhorn Hospital in Bangkok, Thailand. Ms. Stanford-Moore, Mr. Hsu, and Mr. Chang are affiliated with the Liver Center of Huntington Medical Research Institutes in Pasadena, California. Dr. Blatt is affiliated with Alios Biopharma in South San Francisco, California.
Lawrence Mitchell BlattDr. Tong is affiliated with the Liver Center of Huntington Medical Research Institutes in Pasadena, California and with the Pfleger Liver Institute and the Division of Digestive Diseases at the David Geffen School of Medicine of the University of California in Los Angeles, California. Dr. Siripongsakun is affiliated with the Pfleger Liver Institute and the Division of Digestive Diseases at the David Geffen School of Medicine of the University of California in Los Angeles, California and with Chalubhorn Hospital in Bangkok, Thailand. Ms. Stanford-Moore, Mr. Hsu, and Mr. Chang are affiliated with the Liver Center of Huntington Medical Research Institutes in Pasadena, California. Dr. Blatt is affiliated with Alios Biopharma in South San Francisco, California.
University of California System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsHepatitis B virus (HBV) infection is a common cause of hepatocellular carcinoma (HCC) in the United States. This study evaluated the impact of surveillance and treatment on HBV-infected HCC patients and identified factors associated with survival.

methodsFrom 1981 to 2010, 166 hepatitis B surface antigen (HBsAg)-positive HCC patients were evaluated. Fifty-eight patients had HCC detected by surveillance, while 108 patients presented with HCC.

resultsCompared to patients detected by surveillance, those presenting with HCC had more symptoms (65.7% vs 41.4%; P=.002), were more frequently outside of Milan criteria (73.7% vs 29.6%; P<.001), more often presented with diffuse tumors (23.2% vs 1.9%; P<.001), and had a shortened median survival time (9.5 months vs 18.7 months; P=.003). Patients who presented with diffuse tumors were younger and more often male (P=.002-.007), had a higher alpha-fetoprotein (AFP) level (P=.023), and had a median survival time of only 1.68 months. By multivariate analysis, factors that were significantly associated with mortality included diffuse tumors (hazard ratio [HR], 6.30; 95% confidence interval [CI], 3.14-12.66; P<.001), being outside of Milan criteria (HR, 2.02; 95% CI, 1.26-3.23; P=.005), albumin level (HR per 1 standard deviation decrease, 1.4; 95% CI, 1.15-1.72; P=.001), AFP level (HR per 1 log standard deviation increase, 1.38; 95% CI, 1.13-1.67; P=.001), and receiving liver transplantation versus other treatments (HR, 0.08-0.38; 95% CI, 0.03-0.87; P<.001 to P=.022).

conclusionIn the United States, HBV-related HCC is a common malignancy, especially among Asian immigrants. Identification of HBsAgpositive subjects and routine HCC surveillance are essential for improving survival in these patients.

Indexed as

Hepatitis B virushepatocellular carcinomaliver transplantationlocoregional therapyresectionsurveillancesurvival

Identifiers

PMID24693270
PMCPMC3971894
OpenAlexW981524326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.